Orchard Therapeutics Banks On Lentiviral Gene Therapy Potential
Armed with $110m raised in a Series B financing at the end of 2017, UK biotech Orchard Therapeutics is accelerating its efforts to lentiviral gene therapeutics into patients.
Armed with $110m raised in a Series B financing at the end of 2017, UK biotech Orchard Therapeutics is accelerating its efforts to lentiviral gene therapeutics into patients.